{"id":"rivastigmine-transdermal-patch","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Vomiting"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"10-15","effect":"Anorexia/weight loss"},{"rate":"15-20","effect":"Application site erythema"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL636","moleculeType":"Small molecule","molecularWeight":"250.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting acetylcholinesterase and butyrylcholinesterase, rivastigmine increases the concentration of acetylcholine in synaptic clefts, enhancing cholinergic neurotransmission. This is thought to improve cognitive function and slow cognitive decline in Alzheimer's disease and Parkinson's disease dementia by compensating for the loss of cholinergic neurons characteristic of these conditions.","oneSentence":"Rivastigmine is a cholinesterase inhibitor that increases acetylcholine levels in the brain by blocking the enzyme that breaks it down.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:24.791Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate Alzheimer's disease"},{"name":"Mild to moderate Parkinson's disease dementia"}]},"trialDetails":[{"nctId":"NCT07464340","phase":"PHASE1","title":"Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment","status":"COMPLETED","sponsor":"Zodiac Produtos Farmaceuticos S.A.","startDate":"2023-05-12","conditions":"Bioequivalence Study in Healthy Subjects","enrollment":68},{"nctId":"NCT04226248","phase":"PHASE3","title":"CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)","status":"COMPLETED","sponsor":"University of Bristol","startDate":"2020-01-02","conditions":"Parkinson Disease","enrollment":600},{"nctId":"NCT04366518","phase":"EARLY_PHASE1","title":"Toward a Computationally-Informed, Personalized Treatment for Hallucinations","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-07-15","conditions":"Hallucinations, Auditory, Psychosis","enrollment":35},{"nctId":"NCT06702124","phase":"PHASE3","title":"A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease","status":"RECRUITING","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2023-12-01","conditions":"Alzheimer Disease","enrollment":348},{"nctId":"NCT02989402","phase":"PHASE4","title":"A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-31","conditions":"Alzheimer's Disease","enrollment":100},{"nctId":"NCT05768126","phase":"PHASE4","title":"Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2021-09-29","conditions":"Depressive Disorder","enrollment":100},{"nctId":"NCT05883124","phase":"PHASE1","title":"Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","startDate":"2023-04-17","conditions":"Bioequivalence","enrollment":38},{"nctId":"NCT03840837","phase":"PHASE4","title":"Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2019-05-02","conditions":"Parkinson Disease, Parkinson Disease Dementia","enrollment":31},{"nctId":"NCT05853341","phase":"PHASE1","title":"Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2023-05-02","conditions":"Healthy","enrollment":48},{"nctId":"NCT04732182","phase":"NA","title":"Telerehabilitation Alzheimer's Disease Feasibility (TADF)","status":"UNKNOWN","sponsor":"Bright Cloud International Corp","startDate":"2022-02-16","conditions":"Alzheimer Disease, Healthy Aging","enrollment":14},{"nctId":"NCT03915626","phase":"EARLY_PHASE1","title":"Effect of Heat on Rivastigmine TDS Products","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2019-10-04","conditions":"Bioavailability","enrollment":7},{"nctId":"NCT04189666","phase":"PHASE1, PHASE2","title":"Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative Delirium","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-11-18","conditions":"Delirium","enrollment":180},{"nctId":"NCT03659435","phase":"PHASE1","title":"Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","startDate":"2018-08-22","conditions":"Bioequivalence","enrollment":58},{"nctId":"NCT01852110","phase":"PHASE2","title":"Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-22","conditions":"Alzheimer's Disease","enrollment":240},{"nctId":"NCT03573050","phase":"PHASE1","title":"Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","startDate":"2018-05-16","conditions":"Bioequivalence","enrollment":36},{"nctId":"NCT01585272","phase":"PHASE4","title":"Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Alzheimer's Dementia","enrollment":121},{"nctId":"NCT01670526","phase":"PHASE3","title":"Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2012-12","conditions":"Traumatic Brain Injury, Cognitive Impairment","enrollment":94},{"nctId":"NCT00099242","phase":"PHASE3","title":"Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-11","conditions":"Alzheimer's Disease, Dementia, Alzheimer Type","enrollment":1040},{"nctId":"NCT01519271","phase":"PHASE4","title":"Mild Cognitive Impairment in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-12","conditions":"Parkinson's Disease, Mild Cognitive Impairment","enrollment":28},{"nctId":"NCT00731224","phase":"PHASE4","title":"Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-07","conditions":"Alzheimer's Disease","enrollment":380},{"nctId":"NCT01602198","phase":"NA","title":"Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2011-06","conditions":"Mild Cognitive Disorder, Mild Cognitive Impairment","enrollment":1},{"nctId":"NCT01047579","phase":"PHASE4","title":"A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Alzheimer's Disease","enrollment":51},{"nctId":"NCT00219232","phase":"PHASE3","title":"An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-02","conditions":"Alzheimer's Disease","enrollment":868},{"nctId":"NCT01529619","phase":"PHASE4","title":"Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Alzheimer's Disease","enrollment":52},{"nctId":"NCT01614886","phase":"PHASE3","title":"Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-07","conditions":"Alzheimer's Disease","enrollment":216},{"nctId":"NCT01487317","phase":"PHASE3","title":"Rivastigmine in the Management of Delirium","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-06","conditions":"Delirium","enrollment":23},{"nctId":"NCT00428389","phase":"PHASE3","title":"Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-01","conditions":"Alzheimer's Disease","enrollment":262},{"nctId":"NCT01348282","phase":"PHASE4","title":"Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2011-05","conditions":"Neurocognitive Disturbance, HIV Infection","enrollment":33},{"nctId":"NCT00423085","phase":"PHASE3","title":"Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Alzheimer's Disease","enrollment":859},{"nctId":"NCT00948766","phase":"PHASE4","title":"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-07","conditions":"Alzheimer's Disease","enrollment":716},{"nctId":"NCT00506415","phase":"PHASE3","title":"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-06","conditions":"Alzheimer Disease","enrollment":1584},{"nctId":"NCT00767091","phase":"PHASE3","title":"Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2009-03","conditions":"Parkinson's Disease, Apathy, no Dementia","enrollment":40},{"nctId":"NCT01183806","phase":"PHASE3","title":"Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients","status":"COMPLETED","sponsor":"Federal University of Bahia","startDate":"2010-07","conditions":"Alzheimer Disease","enrollment":40},{"nctId":"NCT00881205","phase":"PHASE4","title":"Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-04","conditions":"Multiple Sclerosis, Cognitive Impairment","enrollment":86},{"nctId":"NCT00623103","phase":"PHASE3","title":"Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":"Parkinson's Disease Dementia","enrollment":583},{"nctId":"NCT00622713","phase":"PHASE4","title":"A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":"Alzheimer's Disease","enrollment":228},{"nctId":"NCT00549601","phase":"PHASE4","title":"Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-09","conditions":"Alzheimer's Disease","enrollment":142},{"nctId":"NCT01025466","phase":"PHASE4","title":"Exelon Patch and Combination With Memantine Comparative Trial","status":"COMPLETED","sponsor":"Inha University Hospital","startDate":"2008-12","conditions":"Alzheimer's Disease","enrollment":206}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"BRADYKINESIA"},{"count":2,"reaction":"FIBROMA"},{"count":2,"reaction":"GAIT DISTURBANCE"},{"count":2,"reaction":"HALLUCINATION"},{"count":2,"reaction":"INSOMNIA"},{"count":2,"reaction":"MOBILITY DECREASED"},{"count":2,"reaction":"MUSCLE RIGIDITY"},{"count":2,"reaction":"ON AND OFF PHENOMENON"},{"count":2,"reaction":"PARKINSON^S DISEASE"},{"count":2,"reaction":"PRODUCT PRESCRIBING ERROR"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Exelon®","Exelon transdermal patch","Cholinesterase Inhibitor","exelon patch","Exelon, Prometax"],"phase":"marketed","status":"active","brandName":"Rivastigmine transdermal patch","genericName":"Rivastigmine transdermal patch","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivastigmine is a cholinesterase inhibitor that increases acetylcholine levels in the brain by blocking the enzyme that breaks it down. Used for Mild to moderate Alzheimer's disease, Mild to moderate Parkinson's disease dementia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}